Expert Addresses How Addition of Umbralisib, Ublituximab Could Affect Treatement with Ibrutinib

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She addressed how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.